Howard W Robin sold $431k of NKTR
President & CEO at NEKTAR THERAPEUTICS. 11,832 shares at an average of $36.42, traded Sep 4, 2025, filed Sep 8, 2025.
Score components
- +25RoleCEO
- +17Trade size$431k at market
- +5Share of holdings soldSold 17% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +27.6%, 3m +29.2%, 6m +56.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-113691, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 4, 2025 | SOpen-market sale Common Stock10b5-1 | -1,923 | $32.37 | $62k | 65,917 | Sep 8, 2025 |
| Sep 4, 2025 | SOpen-market sale Common Stock10b5-1 | -1,496 | $33.54 | $50k | 64,421 | Sep 8, 2025 |
| Sep 4, 2025 | SOpen-market sale Common Stock10b5-1 | -613 | $34.40 | $21k | 63,808 | Sep 8, 2025 |
| Sep 4, 2025 | SOpen-market sale Common Stock10b5-1 | -1,134 | $35.80 | $41k | 62,674 | Sep 8, 2025 |
| Sep 5, 2025 | SOpen-market sale Common Stock10b5-1 | -3,304 | $37.87 | $125k | 59,370 | Sep 8, 2025 |
| Sep 5, 2025 | SOpen-market sale Common Stock10b5-1 | -2,226 | $38.82 | $86k | 57,144 | Sep 8, 2025 |
| Sep 5, 2025 | SOpen-market sale Common Stock10b5-1 | -1,136 | $39.89 | $45k | 56,008 | Sep 8, 2025 |
Related signals
Other insiders at NEKTAR THERAPEUTICS and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | NEKTAR THERAPEUTICS | Howard W Robin President & CEO | $30k 418 shares | -1% | |
| 23Weak | NEKTAR THERAPEUTICS | Jonathan Zalevsky Chief R&D Officer | $13k 186 shares | -2% | |
| 29Weak | NEKTAR THERAPEUTICS | Jonathan Zalevsky Chief R&D Officer | $398k 5,681 shares | -37% | |
| 48Moderate | NEKTAR THERAPEUTICS | Howard W Robin President & CEO | $1.2M 20,000 shares | -27% | |
| 28Weak | NEKTAR THERAPEUTICS | Jonathan Zalevsky Chief R&D Officer | $336k 5,538 shares | -26% | |
| 38Weak | NEKTAR THERAPEUTICS | Howard W Robin President & CEO | $29k 444 shares | -1% | |
| 23Weak | NEKTAR THERAPEUTICS | Jonathan Zalevsky Chief R&D Officer | $13k 199 shares | -1% | |
| 38Weak | NEKTAR THERAPEUTICS | Howard W Robin President & CEO | $31k 423 shares | -1% | |
| 23Weak | NEKTAR THERAPEUTICS | Jonathan Zalevsky Chief R&D Officer | $13k 180 shares | -1% | |
| 11Weak | NEKTAR THERAPEUTICS | Jonathan Zalevsky Chief R&D Officer | $138k 3,867 shares | -15% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.